ACE2 Antibody
Code | Size | Price |
---|
PSI-3227-0.02mg | 0.02mg | £150.00 |
PSI-3227-0.1mg | 0.1mg | £449.00 |
Overview
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Images
Documents
Further Information
Antibody validated: Western Blot in human, mouse and rat samples; Immunohistochemistry in human samples; Immunofluorescence in human samples. All other applications and species not yet tested.
ACE2 Antibody: Angiotensin-converting enzyme 2 (ACE2) plays a central role in vascular, renal, and myocardial physiology. In contrast to its homolog ACE, ACE2 expression is restricted to heart, kidney, and testis. Recently. ACE2 has also been shown to be a functional receptor of the SARS coronavirus. Homology modeling shows 2019-nCoV has a similar receptor-binding domain structure as SARS-CoV, which suggests COVID-19 (2019-nCoV) may use ACE2 as a receptor in humans for infection. The normal function of ACE2 is to convert the inactive vasoconstrictor angiotensin I (AngI) to Ang1-9 and the active form AngII to Ang1-7, unlike ACE, which converts AngI to AngII. While the role of these vasoactive peptides is not well understood, lack of ACE2 expression in ace2-/ace2- mice leads to severely reduced cardiac contractility, indicating its importance in regulating heart function.
- Donoghue et al. Circ. Res. 2000;87:1-9.
- Tipnis et al. J Biol. Chem. 2000;275:33238-43.
- Li et al. Nature 2003;426:450-4.
- Lu et al. The Lancet 2020 (published online).
- Crackower et al. Nature 2002;417:822-8.
The immunogen is located within the first 50 amino acids of ACE2.
Observed: 130 kD (7 N-linked glycosylation)
Related Products
Product Name | Product Code | Supplier | ACE2 Peptide | PSI-3227P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|